Home

Group photo

Sepsis is a potentially fatal immune response to bacteria and fungi infection in the human body. Early diagnosis is crucial. SMARTDIAGNOS will achieve 1-3 hours diagnosis time, 95% sensitivity, and 99% accuracy, decreasing morbidity and mortality up to 20%.
Smartdiagnos

Sepsis is a potentially fatal immune response to bacteria and fungi infection in the human body. Early diagnosis is crucial. SMARTDIAGNOS will achieve 1-3 hours diagnosis time, 95% sensitivity, and 99% accuracy, decreasing morbidity and mortality up to 20%.

Smartdiagnos

Sepsis is a potentially fatal immune response to bacteria and fungi infection in the human body. Early diagnosis is crucial. SMARTDIAGNOS will achieve 1-3 hours diagnosis time, 95% sensitivity, and 99% accuracy, decreasing morbidity and mortality up to 20%.

Smartdiagnos

Sepsis is a potentially fatal immune response to bacteria and fungi infection in the human body. Early diagnosis is crucial. SMARTDIAGNOS will achieve 1-3 hours diagnosis time, 95% sensitivity, and 99% accuracy, decreasing morbidity and mortality up to 20%.

SMARTDIAGNOS

Sepsis is a potentially fatal immune response to bacteria and fungi infection in the human body. Early diagnosis is crucial. SMARTDIAGNOS will achieve 1-3 hours diagnosis time, 95% sensitivity, and 99% accuracy, decreasing morbidity and mortality up to 20%.

Overview of SmartDiagnos

In SmartDiagnos we aim to improve current commercially available PCR systems for infection diagnostics, by integrating the necessary systems into one device. Additionally, by using recently developed technological advances, the project aims to reach new levels concerning sensitivity and specificity. This shall allow for fast and easy pathogen identification.

Read more

Contact:

Anders Wolff

Anders Wolff
Associate Professor
DTU Nanotech
+45 4525 6305

 Mette Christiansen
Mette Christiansen
Project support
DTU Nanotech
+45 5244 1955

EU emblem 

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 687697.

The project has 10 partners from 5 EU countries.

 Partners:    

CBS  TATAA biocenter  Scandinavian Micro Biodevices 
 Cube dx  Unilabs University of Skövde 
 Charles University
Danube University Krems   DIN